New head of research at Astellas Gene Therapies: "Choosing the right indications is extra important"

Morten Søgaard is leaving Pfizer to join Astellas, where he will be in charge of 100 employees. Going from one of the world largest pharmaceutical firms to a considerably smaller one will be a challenge, he says.
Morten Søgaard is moving from one US coast to another, as he makes a switch from Pfizer to Astellas Gene Therapies | Photo: Jens Panduro
Morten Søgaard is moving from one US coast to another, as he makes a switch from Pfizer to Astellas Gene Therapies | Photo: Jens Panduro
by ulrich quistgaard, translated by daniel pedersen

Morten Søgaard is packing up shop in New York, where he has spent the past 12 years at pharmaceutical giant Pfizer. He’s now replacing the East Coast with the West Coast, as he joins the San Francisco-based development department of Japanese Astellas Gene Therapies.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading